Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

In a post hoc analysis of the phase 2 GRIFFIN study completed at the time of final analysis (median follow-up, 49.6 months), the addition of daratumumab SC to both bortezomib/lenalidomide/dexamethasone (D-VRd) induction/consolidation and R maintenance showed a trend towards the improvement of clinical outcomes versus VRd induction/consolidation and R maintenance among transplant-eligible patients with NDMM, including those with varying high-risk characteristics [ 29 ].
Both ARC‐18 and DFZ treatments enhanced functional outcomes, and while high‐dose ARC‐18 treated mice showed a trend toward better performance in hanging endurance compared to DFZ treated mice (hanging time +7.9%), this difference did not reach statistical significance (Figure 1B ).
However, in an exploratory analysis of high-risk patients (pT3/4), those who received adjuvant therapy ( n = 6) showed a trend towards longer RFS compared to a matched group who did not ( n = 12), although this was not statistically significant (median RFS 15.2 vs. 9.8 months, p = 0.18), highlighting the need for larger, prospective trials.